Compound property enhancement by virtual compound synthesis

During drug discovery, drug candidates are narrowed down over several steps to develop pharmaceutical products. The theoretical chemical space in such steps is estimated to be [Formula: see text]. To cover that space, extensive virtual compound libraries have been developed; however, the compilation of extensive libraries comes at large computational cost. Thus, to reduce the computational cost, researchers have constructed custom-made virtual compound libraries that focus on target diseases. In this study, we develop a system that generates virtual compound libraries from input compounds. When a user inputs a compound, the system recursively applies virtual synthetic reaction rules to the compound to improve its properties. The synthetic pathway can also be traced by the user because the reaction rules in this system are based on real organic synthesis reactions. This system has useful functions for effective drug design, such as structural preservation, allowing the substructures necessary for potency to be maintained. In this paper, to confirm the effect of directional reaction sets, we applied the reaction sets to 100 compounds. Moreover, to confirm that the system can reproduce real synthetic pathways, the synthetic pathways of Ibuprofen and Ofloxacin were explored by inputting isobutyl benzene and 7,8-difluoro-2,3-dihydro-3-methyl-4H-benzoxazine. This application is available at the following URL: http://enh.sekijima-lab.org .

[1]  K. Stewart,et al.  Drug Guru: a computer software program for drug design using medicinal chemistry rules. , 2006, Bioorganic & medicinal chemistry.

[2]  Xing-Jie Liang,et al.  Therapeutic strategies underpinning the development of novel techniques for the treatment of HIV infection. , 2010, Drug discovery today.

[3]  C. Wermuth,et al.  Glossary of terms used in medicinal chemistry (IUPAC Recommendations 1998) , 1998 .

[4]  Peter Ertl,et al.  JSME: a free molecule editor in JavaScript , 2013, Journal of Cheminformatics.

[5]  M. Sekijima,et al.  Pharmacophore Modeling for Anti-Chagas Drug Design Using the Fragment Molecular Orbital Method , 2015, PloS one.

[6]  I M Kapetanovic,et al.  Computer-aided drug discovery and development (CADDD): in silico-chemico-biological approach. , 2008, Chemico-biological interactions.

[7]  Daisuke Kihara,et al.  An iterative compound screening contest method for identifying target protein inhibitors using the tyrosine-protein kinase Yes , 2017, Scientific Reports.

[8]  J. Willmann,et al.  Molecular imaging in drug development , 2008, Nature Reviews Drug Discovery.

[9]  I. Hayakawa,et al.  Synthesis and Antibacterial Activities of Substituted 7-Oxo-2, 3-dihydro-7H-pyrido [1, 2, 3-de] [1, 4] benzoxazine-6-carboxylic Acids , 1984 .

[10]  J. Powers,et al.  Fluoroquinolone-resistant Campylobacter species and the withdrawal of fluoroquinolones from use in poultry: a public health success story. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[11]  Robert J. Jilek,et al.  AllChem: generating and searching 1020 synthetically accessible structures , 2007, J. Comput. Aided Mol. Des..

[12]  Robert D. Clark,et al.  Virtual Compound Libraries: A New Approach to Decision Making in Molecular Discovery Research , 1998, J. Chem. Inf. Comput. Sci..

[13]  Kimito Funatsu,et al.  A Novel Approach to Retrosynthetic Analysis Using Knowledge Bases Derived from Reaction Databases , 1999, J. Chem. Inf. Comput. Sci..

[14]  T. Ishida,et al.  In silico, in vitro, X-ray crystallography, and integrated strategies for discovering spermidine synthase inhibitors for Chagas disease , 2017, Scientific Reports.

[15]  S S Adams,et al.  The Propionic Acids: A Personal Perspective , 1992, Journal of clinical pharmacology.

[16]  G. V. Paolini,et al.  Quantifying the chemical beauty of drugs. , 2012, Nature chemistry.

[17]  Lorenz C. Blum,et al.  970 million druglike small molecules for virtual screening in the chemical universe database GDB-13. , 2009, Journal of the American Chemical Society.

[18]  W. Guida,et al.  The art and practice of structure‐based drug design: A molecular modeling perspective , 1996, Medicinal research reviews.

[19]  Brian K. Shoichet,et al.  ZINC - A Free Database of Commercially Available Compounds for Virtual Screening , 2005, J. Chem. Inf. Model..

[20]  Charles C. Persinger,et al.  How to improve R&D productivity: the pharmaceutical industry's grand challenge , 2010, Nature Reviews Drug Discovery.

[21]  Zhengwei Peng,et al.  Very large virtual compound spaces: construction, storage and utility in drug discovery. , 2013, Drug discovery today. Technologies.

[22]  Kun-Yi Hsin,et al.  Identification of potential inhibitors based on compound proposal contest: Tyrosine-protein kinase Yes as a target , 2015, Scientific Reports.

[23]  Asher Mullard New drugs cost US$2.6 billion to develop , 2014, Nature Reviews Drug Discovery.